Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM).
新澤西州蒙茅斯交界處,2024年3月26日(環球新聞專線)——臨床階段的腫瘤公司阿亞拉制藥公司(OTCQX:ADXS)今天宣佈,完成了先前宣佈向Immunome, Inc.(納斯達克股票代碼:IMNM)出售的 AL102 及相關候選藥物 AL101。
As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments.
根據出售條款,Ayala從Immunome獲得了2000萬美元的現金和2,175,489股Immunome普通股,Immunome承擔了與 AL102 相關的特定負債。Ayala還可能額外獲得高達3,750萬美元的開發和商業里程碑付款。
"We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and CEO of Ayala Pharmaceuticals. "I am deeply grateful to the team at Ayala for the work they have done over the last several years to assemble compelling clinical data and reach this point."
阿亞拉制藥總裁兼首席執行官肯·柏林表示:“我們很高興Immunome經驗豐富的團隊現在能夠推進 AL102 的發展。”“我深切感謝Ayala團隊在過去幾年中爲收集令人信服的臨床數據並實現這一目標所做的工作。”
A.G.P./Alliance Global Partners acted as strategic advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction.
A.G.P./Alliance Global Partners擔任了與該交易有關的阿亞拉制藥公司的戰略顧問。
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company with expertise in developing small molecule therapeutics for rare tumors and aggressive cancers. Following the completed sale of AL102, an oral gamma secretase inhibitor in Phase 3 clinical development, and AL 101 to Immunome, Inc., Ayala's clinical assets include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). For more information, visit .
關於 Ayala Pharmicals, Inc
Ayala Pharmaceuticals, Inc. 是一家臨床階段的腫瘤學公司,在開發針對罕見腫瘤和侵襲性癌症的小分子療法方面擁有專業知識。繼向Immunome, Inc. 完成向Immunome, Inc.出售口服伽瑪分泌酶抑制劑 AL102 和AL 101之後,Ayala的臨床資產包括阿巴胞他拉濱(BST-236),這是一種用於不適合的急性髓系白血病(AML)一線治療的新型專有抗代謝物。欲了解更多信息,請訪問。
Cautionary Statement Regarding Forward-Looking Statements
關於前瞻性陳述的警示聲明
The statement contained in this release that Ayala may receive up to $37.5 million after the consummation of the sale of AL 102 to Immunome upon the achievement of certain development and commercial milestones may be considered a forward-looking statement, as such involving a number of risks and uncertainties. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation, risks and uncertainties related to: the potential benefit of the sale to Immunome and whether the milestones relating to such potential payments will be realized, which will depend on factors such as Immunome's ability to grow and successfully execute on its business plan, including the development and commercialization of the AL101 and AL102 programs. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿中關於在實現某些開發和商業里程碑後向Immunome完成向Immunome出售AL 102後Ayala可能獲得高達3,750萬美元的收入的聲明可以被視爲前瞻性陳述,因此涉及許多風險和不確定性。前瞻性陳述基於當前的信念和假設,這些信念和假設存在風險和不確定性,不能保證未來的表現。由於各種因素,包括但不限於與出售Immunome的潛在收益以及與此類潛在付款相關的風險和不確定性,實際結果可能與任何前瞻性陳述中包含的結果存在重大差異,這將取決於Immunome的增長能力和成功執行其業務計劃的能力等因素,包括 AL101 和 AL102 計劃的開發和商業化。除非適用法律要求,否則公司沒有義務修改或更新任何前瞻性陳述,也沒有義務做出任何其他前瞻性陳述,無論是由於新信息、未來事件還是其他原因。
Contacts:
Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
聯繫人:
阿亞拉制藥:
+1-857-444-0553
info@ayalapharma.com
Ayala Media:
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
917-679-9282
阿亞拉媒體:
蒂姆·麥卡錫
LifeSci 顧問有限公司
tim@lifesciadvisors.com
917-679-9282